Prevention and treatment of bronchopulmonary dysplasia: Contemporary status and future outlook

Lung

Volumn 186, Issue 2, 2008, Pages 75-89

  Cerny, Laura ^a   Torday, John S ^a   Rehan, Virender K ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Chronic lung disease; Hyperoxia; Inhaled nitric oxide; Parathyroid hormone related protein; Peroxisome proliferator activated receptor ; Prematurity; Surfactant; Volutrauma

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AZITHROMYCIN; BERACTANT; BRONCHODILATING AGENT; CAFFEINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIURETIC AGENT; FUROSEMIDE; INOSITOL; LUCINACTANT; LUNG SURFACTANT; NITRIC OXIDE; PARATHYROID HORMONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; PORACTANT; RETINOL; SALBUTAMOL; STEROID;

APPLICATION SITE BLEEDING; APPLICATION SITE INFLAMMATION; APPLICATION SITE PAIN; CEREBRAL PALSY; CHORIOAMNIONITIS; CLINICAL TRIAL; DEVELOPMENTAL DISORDER; FLUID THERAPY; HEMOSTASIS; HUMAN; INTERMITTENT POSITIVE PRESSURE VENTILATION; INTRACRANIAL HYPERTENSION; LUNG ALVEOLUS; LUNG DYSPLASIA; MUCOSAL DISEASE; NEUROLOGICAL COMPLICATION; NUTRITIONAL SUPPORT; OXYGEN THERAPY; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETINOL DEFICIENCY; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; VOMITING;

BRONCHOPULMONARY DYSPLASIA; HOMEOSTASIS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; PARATHYROID HORMONE-RELATED PROTEIN; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 43349092682     PISSN: 03412040     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00408-007-9069-z     Document Type: Review

References (100)

1. Jobe AH, Bancalari E (2001) Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163:1723-1729
2. Walsh MC, Szefler S, Davis J, Allen M, Van ML, Abman S, Blackmon L, Jobe A (2006) Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117:S52-S56
3. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G (1995) Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 126:605-610
4. Chye JK, Gray PH (1995) Rehospitalization and growth of infants with bronchopulmonary dysplasia: a matched control study. J Paediatr Child Health 31:105-111
5. Gregoire MC, Lefebvre F, Glorieux J (1998) Health and developmental outcomes at 18 months in very preterm infants with bronchopulmonary dysplasia. Pediatrics 101:856-860
6. Short EJ, Klein NK, Lewis BA, Fulton S, Eisengart S, Kercsmar C, Baley J, Singer LT (2003) Cognitive and academic consequences of bronchopulmonary dysplasia and very low birth weight: 8-year-old outcomes. Pediatrics 112:e359
7. Northway WH Jr, Rosan RC, Porter DY (1967) Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276:357-368
8. Husain AN, Siddiqui NH, Stocker JT (1998) Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Pathol 29:710-717
9. Ambalavanan N, Tyson JE, Kennedy KA, Hansen NI, Vohr BR, Wright LL, Carlo WA (2005) Vitamin A supplementation for extremely low birth weight infants: outcome at 18 to 22 months. Pediatrics 115:e249-e254
10. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Mayock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE (2006) Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355:343-353
11. Barrington KJ, Finer NN (1998) Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol 25:177-202
12. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC (2005) Impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk for chronic lung disease. Pediatrics 115:655-661
13. Torday JS, Torres E, Rehan VK (2003) The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro. Pediatr Pathol Mol Med 22:189-207
14. Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, Epstein MF, Fitzhardinge PM, Hansen CB, Hansen TN (1987) Is chronic lung disease in low birth weight infants preventable? A survey of eight centers. Pediatrics 79:26-30
15. Van Marter LJ, Allred EN, Pagano M, Sanocka U, Parad R, Moore M, Susser M, Paneth N, Leviton A (2000) Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease? The Neonatology Committee for the Developmental Network. Pediatrics 105:1194-1201
16. Aly H, Massaro AN, Patel K, El-Mohandes AA (2005) Is it safer to intubate premature infants in the delivery room? Pediatrics 115:1660-1665
17. Aly H (2007) Is there a strategy for preventing bronchopulmonary dysplasia? Absence of evidence is not evidence of absence. Pediatrics 119:818-820
18. Kinsella JP, Greenough A, Abman SH (2006) Bronchopulmonary dysplasia. Lancet 367:1421-1431
19. Davis PG, Henderson-Smart DJ (2003) Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. Cochrane Database Syst Rev CD000143
20. Davis PG, Lemyre B, De Paoli AG (2001) Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev CD003212
21. Kulkarni A, Ehrenkranz RA, Bhandari V (2006) Effect of introduction of synchronized nasal intermittent positive-pressure ventilation in a neonatal intensive care unit on bronchopulmonary dysplasia and growth in preterm infants. Am J Perinatol 23:233-240
22. Bhandari A, Bhandari V (2007) Bronchopulmonary dysplasia: an update. Indian J Pediatr 74:73-77
23. Kamlin CO, Davis PG (2004) Long versus short inspiratory times in neonates receiving mechanical ventilation. Cochrane Database Syst Rev CD004503
24. Miller JD, Carlo WA (2007) Safety and effectiveness of permissive hypercapnia in the preterm infant. Curr Opin Pediatr 19:142-144
25. 2 targets during the first seven days of life. Biol Neonate 90:218-225
26. Greenough A, Sharma A (2007) What is new in ventilation strategies for the neonate? Eur J Pediatr 166:991-996
27. Courtney SE, Durand DJ, Asselin JM, Hudak ML, Aschner JL, Shoemaker CT (2002) High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med 347:643-652
28. Johnson AH, Peacock JL, Greenough A, Marlow N, Limb ES, Marston L, Calvert SA (2002) High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 347:633-642
29. Moriette G, Paris-Llado J, Walti H, Escande B, Magny JF, Cambonie G, Thiriez G, Cantagrel S, Lacaze-Masmonteil T, Storme L, Blanc T, Liet JM, Andre C, Salanave B, Breart G (2001) Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics 107:363-372
30. McCallion N, Davis PG, Morley CJ (2005) Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev CD003666
31. Deulofeut R, Critz A, Adams-Chapman I, Sola A (2006) Avoiding hyperoxia in infants < or = 1250 g is associated with improved short- and long-term outcomes. J Perinatol 26:700-705
32. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM (2003) Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349:959-967
33. Greenspan JS, Goldsmith JP (2006) Oxygen therapy in preterm infants: hitting the target. Pediatrics 118:1740-1741
34. Soll RF, Blanco F (2001) Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev CD000144
35. Suresh GK, Soll RF (2002) Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents? Paediatr Drugs 4:485-492
36. Sinha SK, Lacaze-Masmonteil T, Soler A, Wiswell TE, Gadzinowski J, Hajdu J, Bernstein G, Sanchez-Luna M, Segal R, Schaber CJ, Massaro J, d'Agostino R (2005) A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115:1030-1038
37. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A, Kornacka MK, Merritt TA, Segal R, Schaber CJ, Tsai H, Massaro J, d'Agostino R (2005) A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics 115:1018-1029
38. Moya F, Sinha S, Gadzinowski J, d'Agostino R, Segal R, Guardia C, Mazela J, Liu G (2007) One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics 119:e1361-e1370
39. Pfister RH, Soll RF, Wiswell T (2007) Protein containing synthetic surfactant versus animal derived surfactant extract for the prevention and treatment of respiratory distress syndrome. Cochrane Database Syst Rev CD006069
40. Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev CD001456
41. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Auten RL, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH (2006) Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355:354-364
42. Kinsella JP, Abman SH (2007) Inhaled nitric oxide in the premature newborn. J Pediatr 151:10-15
43. Steinhorn RH, Kinsella JP (2007) Use of inhaled nitric oxide in the preterm infant. Neoreviews 8:e247-e252
44. Truog WE (2007) Inhaled nitric oxide for the prevention of bronchopulmonary dysplasia. Expert Opin Pharmacother 8:1505-1513
45. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W (2006) Caffeine therapy for apnea of prematurity. N Engl J Med 354:2112-2121
46. Crowley PA (1995) Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 173:322-335
47. Roberts D, Dalziel S (2006) Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 3:CD004454
48. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev CD001146
49. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, Couser RJ, Garland JS, Rozycki HJ, Leach CL, Backstrom C, Shaffer ML (2004) Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics 114:1649-1657
50. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev CD001144
51. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev CD001145
52. Shah V, Ohlsson A, Halliday HL, Dunn MS (2007) Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev CD001969
53. Shah SS, Ohlsson A, Halliday H, Shah VS (2003) Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev CD002058
54. Shah SS, Ohlsson A, Halliday H, Shah VS (2003) Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev CD002057
55. Watterberg KL, Demers LM, Scott SM, Murphy S (1996) Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 97:210-215
56. Kallapur SG, Jobe AH (2006) Contribution of inflammation to lung injury and development. Arch Dis Child Fetal Neonatal Ed 91:F132-F135
57. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr (2005) Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J 24:1033-1039
58. Viscardi R, Manimtim W, He JR, Hasday JD, Sun CC, Joyce B, Pierce RA (2006) Disordered pulmonary myofibroblast distribution and elastin expression in preterm infants with Ureaplasma urealyticum pneumonitis. Pediatr Dev Pathol 9:143-151
59. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL (2003) Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev CD003744
60. Ballard HO, Anstead MI, Shook LA (2007) Azithromycin in the extremely low birth weight infant for the prevention of bronchopulmonary dysplasia: a pilot study. Respir Res 8:41
61. Brion LP, Primhak RA, Yong W (2006) Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 3:CD001694
62. Brion LP, Primhak RA, Ambrosio-Perez I (2002) Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev CD001817
63. Brion LP, Primhak RA (2000) Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev CD001453
64. Ng GY, da S, Ohlsson A (2001) Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev CD003214
65. Lai NM, Rajadurai SV, Tan KH (2006) Increased energy intake for preterm infants with (or developing) bronchopulmonary dysplasia/ chronic lung disease. Cochrane Database Syst Rev 3:CD005093
66. Mataloun MM, Rebello CM, Mascaretti RS, Dohlnikoff M, Leone CR (2006) Pulmonary responses to nutritional restriction and hyperoxia in premature rabbits. J Pediatr (Rio J) 82:179-185
67. Biniwale MA, Ehrenkranz RA (2006) The role of nutrition in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 30:200-208
68. Tyson JE, Wright LL, Oh W, Kennedy KA, Mele L, Ehrenkranz RA, Stoll BJ, Lemons JA, Stevenson DK, Bauer CR, Korones SB, Fanaroff AA (1999) Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 340:1962-1968
69. Darlow BA, Graham PJ (2002) Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev CD000501
70. Hallman M, Arjomaa P, Hoppu K (1987) Inositol supplementation in respiratory distress syndrome: relationship between serum concentration, renal excretion, and lung effluent phospholipids. J Pediatr 110:604-610
71. Howlett A, Ohlsson A (2003) Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev CD000366
72. Davis JM (2002) Role of oxidant injury in the pathogenesis of neonatal lung disease. Acta Paediatr Suppl 91:23-25
73. Bolisetty S, Naidoo D, Lui K, Koh TH, Watson D, Whitehall J (2002) Antenatal supplementation of antioxidant vitamins to reduce the oxidative stress at delivery-a pilot study. Early Hum Dev 67:47-53
74. Chappell LC, Seed PT, Briley AL, Kelly FJ, Lee R, Hunt BJ, Parmar K, Bewley SJ, Shennan AH, Steer PJ, Poston L (1999) Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet 354:810-816
75. Suresh GK, Davis JM, Soll RF (2001) Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev CD001968
76. Shah P, Ohlsson A (2001) Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev CD002775
77. Stiskal JA, Dunn MS, Shennan AT, O'Brien KK, Kelly EN, Koppel RI, Cox DW, Ito S, Chappel SL, Rabinovitch M (1998) alpha1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics 101:89-94
78. Levine CR, Gewolb IH, Allen K, Welch RW, Melby JM, Pollack S, Shaffer T, Pilon AL, Davis JM (2005) The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome. Pediatr Res 58:15-21
79. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT (1997) Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 42:348-355
80. Rubin LP, Kovacs CS, De Paepe ME, Tsai SW, Torday JS, Kronenberg HM (2004) Arrested pulmonary alveolar cytodifferentiation and defective surfactant synthesis in mice missing the gene for parathyroid hormone-related protein. Dev Dyn 230:278-289
81. Torday JS, Rehan VK (2004) Deconvoluting lung evolution using functional/comparative genomics. Am J Respir Cell Mol Biol 31:8-12
82. Torday JS, Rehan VK (2002) Stretch-stimulated surfactant synthesis is coordinated by the paracrine actions of PTHrP and leptin. Am J Physiol Lung Cell Mol Physiol 283:L130-L135
83. Torday JS, Torday DP, Gutnick J, Qin J, Rehan V (2001) Biologic role of fetal lung fibroblast triglycerides as antioxidants. Pediatr Res 49:843-849
84. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB (1999) Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 277:C1-C9
85. Bostrom H, Willetts K, Pekny M, Leveen P, Lindahl P, Hedstrand H, Pekna M, Hellstrom M, Gebre-Medhin S, Schalling M, Nilsson M, Kurland S, Tornell J, Heath JK, Betsholtz C (1996) PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis. Cell 85:863-873
86. Boros LG, Torday JS, Paul Lee WN, Rehan VK (2002) Oxygen-induced metabolic changes and transdifferentiation in immature fetal rat lung lipofibroblasts. Mol Genet Metab 77:230-236
87. Rehan V, Torday J (2003) Hyperoxia augments pulmonary lipofibroblast-to-myofibroblast transdifferentiation. Cell Biochem Biophys 38:239-250
88. Rehan VK, Wang Y, Sugano S, Romero S, Chen X, Santos J, Khazanchi A, Torday JS (2005) Mechanism of nicotine-induced pulmonary fibroblast transdifferentiation. Am J Physiol Lung Cell Mol Physiol 289:L667-L676
89. Rehan VK, Wang Y, Patel S, Santos J, Torday JS (2006) Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo. Pediatr Pulmonol 41:558-569
90. Rehan VK, Wang Y, Sugano S, Santos J, Patel S, Sakurai R, Boros LG, Lee WP, Torday JS (2007) In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism. Am J Physiol Lung Cell Mol Physiol 292:L323-L333
91. Rehan VK, rgan-Batra SK, Wang Y, Cerny L, Sakurai R, Santos J, Beloosesky R, Gayle D, Torday JS (2007) A paradoxical temporal response of the PTHrP/PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung. Am J Physiol Lung Cell Mol Physiol 293:L182-L190
92. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM (2001) Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164:1971-1980
93. Stenmark KR, Balasubramaniam V (2005) Angiogenic therapy for bronchopulmonary dysplasia: rationale and promise. Circulation 112:2383-2385
94. Abman SH (2001) Bronchopulmonary dysplasia: "a vascular hypothesis". Am J Respir Crit Care Med 164:1755-1756
95. Thebaud B, Abman SH (2007) Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med 175:978-985
96. Gao Y, Raj JU (2005) Parathyroid hormone-related protein-mediated responses in pulmonary arteries and veins of newborn lambs. Am J Physiol Lung Cell Mol Physiol 289:L60-L66
97. Van HT, Thebaud B (2006) Adult bone marrow-derived stem cells for the lung: implications for pediatric lung diseases. Pediatr Res 59:94R-99R
98. Hennrick KT, Keeton AG, Nanua S, Kijek TG, Goldsmith AM, Sajjan US, Bentley JK, Lama VN, Moore BB, Schumacher RE, Thannickal VJ, Hershenson MB (2007) Lung cells from neonates show a mesenchymal stem cell phenotype. Am J Respir Crit Care Med 175:1158-1164
99. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471
100. Psaty BM, Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357:67-69